1 drug(s) with this reaction
939 total reports
Platelet Count Abnormal has been reported as an adverse reaction across 1 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 939 adverse event reports mention platelet count abnormal in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with platelet count abnormal, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have platelet count abnormal listed in their FDA adverse event reports, sorted by report count:
In addition to platelet count abnormal, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
1 drug(s) manufactured by Amgen Inc have platelet count abnormal listed in their FDA adverse event reports: ROMIPLOSTIM.
There are a combined 939 reports of platelet count abnormal across 1 Amgen Inc drug(s) in the FDA adverse event database.